Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical management of Wilson disease.
Hedera P. Hedera P. Ann Transl Med. 2019 Apr;7(Suppl 2):S66. doi: 10.21037/atm.2019.03.18. Ann Transl Med. 2019. PMID: 31179303 Free PMC article. Review.
WTX101 - an investigational drug for the treatment of Wilson disease.
Weiss KH, Członkowska A, Hedera P, Ferenci P. Weiss KH, et al. Among authors: hedera p. Expert Opin Investig Drugs. 2018 Jun;27(6):561-567. doi: 10.1080/13543784.2018.1482274. Epub 2018 Jun 8. Expert Opin Investig Drugs. 2018. PMID: 29806946 Review.
Wilson's disease: A master of disguise.
Hedera P. Hedera P. Parkinsonism Relat Disord. 2019 Feb;59:140-145. doi: 10.1016/j.parkreldis.2019.02.016. Epub 2019 Feb 14. Parkinsonism Relat Disord. 2019. PMID: 30797706 Review.
Liver transplant for neurologic Wilson disease: Hope or fallacy?
Bandmann O, Weiss KH, Hedera P. Bandmann O, et al. Among authors: hedera p. Neurology. 2020 May 26;94(21):907-908. doi: 10.1212/WNL.0000000000009476. Epub 2020 May 12. Neurology. 2020. PMID: 32398360 No abstract available.
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C. Brownstein MJ, et al. Among authors: hedera p. J Clin Med. 2020 Nov 16;9(11):3682. doi: 10.3390/jcm9113682. J Clin Med. 2020. PMID: 33207828 Free PMC article.
Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale.
Charles D, Tolleson C, Davis TL, Gill CE, Molinari AL, Bliton MJ, Tramontana MG, Salomon RM, Kao C, Wang L, Hedera P, Phibbs FT, Neimat JS, Konrad PE. Charles D, et al. Among authors: hedera p. J Parkinsons Dis. 2012;2(3):215-23. doi: 10.3233/JPD-2012-012095. J Parkinsons Dis. 2012. PMID: 23938229 Free PMC article. Clinical Trial.
187 results